a more rapid deterioration in their fifth and sixth decade of life with their disease-course transitioning from a relapsing-remitting ( RR ) phenotype to a progressive phenotype . In one study , 54 % of women with MS reported a worsening of symptoms during the MT . 11 The clinical evaluation of both disorders is challenging due to overlapping symptoms , which include mood disorders , altered cognition , sleep disturbances , vasomotor symptoms and changes in bladder and sexual function . 14
Systemic lupus erythematosus ( SLE ) is a disease characterised by immune complex deposition in tissues and multiorgan inflammation . It is nine times more common in women than men as it is associated with higher lifetime oestrogen exposure . The usual onset for SLE is well into the reproductive years and flares are common in the early stages of perimenopause . Fatigue , brain fog , joint pain , stiffness , headaches , hair loss , dry skin and mucus membranes are just a few of the crossover symptoms in the MT and SLE . 15 Low bone density is also associated with SLE disease activity and menopause further adds to the risk of more severe bone disease , fragility and fractures . While the experience of the MT is unique for every woman , so too is the clinical course of SLE . In more severe cases of SLE a cytotoxic agent such as cyclophosphamide may be used , which can bring about early menopause due to the associated ovarian damage further aggravating symptoms in both conditions . 15
Hashimoto ’ s thyroiditis ( HT ) is 4-10 times more common in women that in men and can be associated with other autoimmune disorders in about 20 % of women . The prevalence of hypothyroidism reaches its peak for women in midlife . Oestrogen increases serum concentrations of thyroxine binding globulin ( TBG ), which in turn binds thyroid hormone , reducing its availability to tissues . 6 The oscillating oestrogen levels of the MT contribute to variable thyroid function and the symptoms reflect their close relationship , and include increased fat mass , poor sleep , fatigue , dry skin , hair loss , and cognitive difficulties . 14
Building a nutritional foundation
By 2030 , it is projected that approximately 1.2 billion women globally will be experiencing the MT . Over 85 % of these women are expected to experience significant symptoms associated with this transition . 3 As women make up around 80 % of those affected by autoimmune conditions , a multifaceted therapeutic approach is needed to ensure that women are empowered to address their health challenges with their concomitant journey of the MT . 3
Menopause hormonal therapy ( MHT )
INTRODUCING
Meno-Femme
• A comprehensive formula combining six herbal extracts to relieve symptoms associated with menopause .
• Contains Lifenol ® , a patented , sustainably sourced and clinically studied * hops extract .
• Traditional and science-based formula .
• Vegan , low excipient and non-GMO formula .
* References available on request Lifenol ® is a trademark of Givaudan
Hops Shatavari
Gotu kola Sage Zizyphus Maca
BioMedica Nutraceuticals P 1300 884 702 | www . biomedica . com . au